Azhar S, Hwang S F, Reaven E P
Biochem J. 1983 Jun 15;212(3):721-31. doi: 10.1042/bj2120721.
Previous studies have shown that anti microtubule agents disrupt Golgi complexes in hepatocytes and other cells, causing breakdown or vesiculation of Golgi cisternal membranes. Whether this change in the structure of the Golgi membranes is associated with changes in Golgi membrane function is not known. The present study was initiated to investigate this issue; i.e., to determine whether anti-microtubule agents that cause structural changes in Golgi membranes in vivo would, at the same time, affect characteristic enzyme functions of Golgi membranes. To this end, colchicine was given to young rats in vivo and various hepatic subcellular membranes were subsequently isolated and utilized for enzyme assays. Initially it was shown that colchicine (2.5 mg/kg body wt.) given for 5h significantly decreased the activities of the Golgi membrane associated enzymes galactosyl-, sialyl- and N-acetylglucosaminyl-transferases. More detailed experiments indicated that low doses of colchicine (0.8 mg/kg body wt.), although less effective than higher doses, decreased the activities of the terminal glycosylating enzymes maximally at 5h, with partial and complete recovery at 12 and 24h respectively. Treatment in vivo of rats with vinblastine (20 mg/kg body wt.) for 5h mimicked the action of colchicine. Two microsomal glycosylating enzymes (mannosyl and N acetylglucosaminyl transferases) were unaffected by the treatment with colchicine, as were various hepatic 'marker' enzymes such as 5' nucleotidase, glucose 6 phosphatase and succinate: 2-(p iodophenyl)-3-(p nitrophenyl)-5-phenyltetrazolium reductase (succinate dehydrogenase; EC 1.3.99.1), which were found to be enriched in plasma membrane, endoplasmic-reticulum and mitochondrial-membrane fractions respectively. These results show that anti-microtubule agents specifically suppress the activity of Golgi-associated glycosyltransferases in liver. Although it seems likely that these changes are related to the previously observed structural changes in hepatocyte Golgi complexes after colchicine treatment, to what extent the results are linked to the interaction of colchicine with microtubule protein remains to be clarified.
以往的研究表明,抗微管药物会破坏肝细胞和其他细胞中的高尔基体复合物,导致高尔基池膜破裂或形成囊泡。高尔基膜结构的这种变化是否与高尔基膜功能的改变相关尚不清楚。开展本研究以探讨该问题,即确定在体内引起高尔基膜结构变化的抗微管药物是否会同时影响高尔基膜的特征性酶功能。为此,给幼鼠体内注射秋水仙碱,随后分离各种肝亚细胞膜并用于酶活性测定。最初发现,给予秋水仙碱(2.5mg/kg体重)5小时可显著降低与高尔基膜相关的半乳糖基转移酶、唾液酸转移酶和N-乙酰葡糖胺基转移酶的活性。更详细的实验表明,低剂量的秋水仙碱(0.8mg/kg体重)虽然比高剂量效果差,但在5小时时最大程度地降低了末端糖基化酶的活性,在12小时和24小时时分别部分恢复和完全恢复。用长春碱(20mg/kg体重)对大鼠进行体内处理5小时模拟了秋水仙碱的作用。两种微粒体糖基化酶(甘露糖基转移酶和N-乙酰葡糖胺基转移酶)不受秋水仙碱处理的影响,各种肝“标记”酶如5'-核苷酸酶、葡萄糖6-磷酸酶和琥珀酸:2-(对碘苯基)-3-(对硝基苯基)-5-苯基四氮唑还原酶(琥珀酸脱氢酶;EC 1.3.99.1)也不受影响,这些酶分别在质膜、内质网和线粒体膜组分中富集。这些结果表明,抗微管药物特异性抑制肝脏中与高尔基体相关的糖基转移酶的活性。虽然这些变化似乎可能与秋水仙碱处理后肝细胞高尔基复合体中先前观察到的结构变化有关,但结果与秋水仙碱与微管蛋白相互作用的关联程度仍有待阐明。